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epilepsy and neurobehavioural problems
Sébastien Chénier1, Grace Yoon2, Bob Argiropoulos3, Julie Lauzon3, Rachel Laframboise4, Joo Wook Ahn5,
Caroline Mackie Ogilvie5, Anath C Lionel6, Christian R Marshall6, Andrea K Vaags7, Bita Hashemi2, Karine Boisvert4,
Géraldine Mathonnet8, Frédérique Tihy8, Joyce So9, Stephen W Scherer6, Emmanuelle Lemyre8
and Dimitri J Stavropoulos10*Abstract
Background: The chromodomain helicase DNA binding domain (CHD) proteins modulate gene expression via their
ability to remodel chromatin structure and influence histone acetylation. Recent studies have shown that CHD2 protein
plays a critical role in embryonic development, tumor suppression and survival. Like other genes encoding members of
the CHD family, pathogenic mutations in the CHD2 gene are expected to be implicated in human disease. In fact, there
is emerging evidence suggesting that CHD2 might contribute to a broad spectrum of neurodevelopmental disorders.
Despite growing evidence, a description of the full phenotypic spectrum of this condition is lacking.
Methods: We conducted a multicentre study to identify and characterise the clinical features associated with
haploinsufficiency of CHD2. Patients with deletions of this gene were identified from among broadly ascertained
clinical cohorts undergoing genomic microarray analysis for developmental delay, congenital anomalies and/or autism
spectrum disorder.
Results: Detailed clinical assessments by clinical geneticists showed recurrent clinical symptoms, including
developmental delay, intellectual disability, epilepsy, behavioural problems and autism-like features without characteristic
facial gestalt or brain malformations observed on magnetic resonance imaging scans. Parental analysis showed that
the deletions affecting CHD2 were de novo in all four patients, and analysis of high-resolution microarray data derived
from 26,826 unaffected controls showed no deletions of this gene.
Conclusions: The results of this study, in addition to our review of the literature, support a causative role of CHD2
haploinsufficiency in developmental delay, intellectual disability, epilepsy and behavioural problems, with phenotypic
variability between individuals.
Keywords: Autism spectrum disorder, CHD2, Developmental delay, Epilepsy, Learning disabilityBackground
Chromatin remodeling is the dynamic modification of
chromatin architecture essential to many biological pro-
cesses, including cell division, gene expression, and DNA
replication, packaging and repair [1-3]. The chromodo-
main helicase DNA binding (CHD) proteins belong to the* Correspondence: james.stavropoulos@sickkids.ca
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family is defined by the presence of tandem chromo (chro-
matin organisation modifier) domains in the N-terminal
region and a central SNF2-related helicase/ATPase do-
main [4]. The latter is the catalytic core mediating chro-
matin alteration. Members of the CHD family are divided
into three subfamilies according to their additional struc-
tural motifs. (1) CHD1 and CHD2 possess a C-terminal
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main zinc finger domains in their N-terminal regions and
lack a DNA binding domain. (3) CHD5 to CHD9, which
contain diverse additional functional domains such as the
BRK (Brahma and Kismet) domain, SANT-like (switch-
ing-defective protein 3, adaptor 2, nuclear receptor core-
pressor, transcription factor IIIB) domain, CR domain and
DNA binding domain [1,5].
As CHD proteins play pivotal roles in modulating
chromatin structure and are involved in processes such
as gene activation and repression, DNA recombination
and repair, cell-cycle regulation, development and cell
differentiation, dysregulation of these proteins may have
adverse effects on human development. Heterozygous
mutations of the CHD7 gene are known to cause the
multisystem abnormalities associated with autosomal
dominant CHARGE syndrome (coloboma, heart anom-
aly, choanal atresia, retardation, genital and ear anomal-
ies) [OMIM:214800]. Characteristic anomalies include
ocular coloboma, choanal atresia, cranial nerve defects,
distinctive external and inner ear abnormalities, hearing
loss, cardiovascular malformations, intellectual disability
(ID), urogenital anomalies and growth retardation. More
recently, exome sequencing studies have shown loss of
function mutations affecting one allele of CHD8 to be
associated with autism spectrum disorder (ASD) [6-8].
There is emerging evidence showing CHD2 haploin-
sufficiency is associated with neurodevelopmental abnor-
malities. Deletions affecting this gene are very rare, and,
so far, there is only one case report of a child with global
developmental delay, epilepsy and ASD who was found
to have a de novo deletion encompassing the RGMA and
CHD2 genes [9]. However, because of the importance of
RGMA in central nervous system axonal growth, hap-
loinsufficiency of this gene was thought to be a good
candidate to explain the patient’s developmental delay
and seizures. A deletion affecting CHD2 was also re-
ported in the supplemental data derived from genomic
microarray analysis of 996 patients ascertained to have
ASD [10]. This deletion involves CHD2, but not RGMA,
and the patient was reported to have ASD and mild ID
with no history of seizures or language delay. Recent
studies have implicated de novo intragenic sequence mu-
tations in CHD2 in individuals with ID and a range of
epileptic encephalopathies [11-13]. Although there is in-
creasing evidence suggesting that mutations in CHD2
contribute to a broad spectrum of neurodevelopmental
disorders, a description of the full phenotypic spectrum
is lacking.
In order to investigate the role of CHD2 haploinsuffi-
ciency in neurodevelopmental disorders, we describe the
first series of patients with deletions affecting CHD2 from
among a cohort of 42,313 patients broadly ascertained by
clinical genetics laboratories to have developmental delay,intellectual disability, multiple congenital anomalies and/
or ASD. We also present a review of the literature to cor-
relate our patients’ phenotypes with those previously re-
ported with deletions and loss-of-function sequence
mutations affecting this gene.
Methods
We conducted a multicentre study of retrospective gen-
omic copy number variation (CNV) data from six genetic
diagnostics laboratories (see Additional file 1: Table S1), to
collect phenotypic information from patients with dele-
tions affecting CHD2. For all patients, phenotypic infor-
mation was collected from genetics clinic assessments and
medical chart reviews. This study is compliant with the re-
search ethics boards of each participating institution.
Signed informed consent was obtained from all study par-
ticipants or their legal representatives. DNA extracted
from uncultured cells, typically from peripheral blood
lymphocytes, was used to perform genomic CNV analysis
in all participating laboratories. Microarray experiments
were performed according to the manufacturer’s instruc-
tions. As described in Table S1, the microarray platforms
used at each of the six diagnostic centres were oligo-
nucleotide array–based. Deletions were confirmed, and
parental follow-up studies were performed with multiplex
ligation-dependent probe amplification (MLPA), array
comparative genomics hybridization (aCGH) or fluores-
cence in situ hybridization (FISH) analysis. FISH analysis
was performed using fosmid G248P83477D10 or CTD-
2314 N10 bacterial artificial chromosome. We investigated
the frequency of deletions affecting CHD2 in high-
resolution CNV data from among 13 control cohorts
comprising a total of 26,826 individuals [10,14-26].
Results
We reviewed genomic CNV data from six genetic diag-
nostics laboratories that perform microarray analysis for
patients broadly ascertained to have delayed develop-
mental milestones in motor, speech and/or cognition
skills (developmental delay); diagnosis of global develop-
mental delay or ID, multiple congenital anomalies; and/
or ASD. We identified four deletions affecting CHD2 ex-
onic sequences from a total of 42,313 patients analyzed.
The deletions ranged in size from approximately 78 kb
to 237 kb, with only one case also involving the RGMA
gene, and all were found to be de novo (Figure 1). No
other clinically significant CNVs were found in these pa-
tients. The clinical findings in these patients included
developmental delay, learning difficulties or ID in all
four patients, as well as seizures in three patients
(Table 1). The dysmorphic features observed in each of
these patients are described in turn in the subsections
below. However, no characteristic facial gestalt was
found. Brain magnetic resonance imaging (MRI) did not
ASB9P1
LOC100507217
CHD2
MIR3175
RGMA
Patient 1
Patient 2
Patient 3
Patient 4
Pinto et al. 2010
Capelli et al. 2012 
Figure 1 Summary of deletions observed in our patients and reported in the literature.
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data derived from 26,826 individuals from population-
based control cohorts evaluated by high-resolution CNV
analysis did not show deletions affecting exonic se-
quences of CHD2, confirming the extreme rarity of this
deletion in the general population (see Additional file 1:
Table S2).
Patient 1
Patient 1 has a 191-kb de novo deletion involving CHD2,
the ASB9P1 noncoding pseudogene, the uncharacterised
LOC100507217 noncoding gene and microRNA MIR3175
(Figure 1). This 11-year-old girl was referred for medical
genetics evaluation because she had fine and gross motor
delays as well as seizures. She was born by Caesarean sec-
tion at 38 weeks gestation with a birth weight of 2,977 g
(25th percentile) to healthy nonconsanguineous Caucasian
parents. She sat upright at age 1 year, walked at 22 months
and spoke her first words at 3 years. She had learning dis-
abilities with specific deficits in language and mathemat-
ics, and she repeated grade 3. She also had short-term
memory problems, a short attention span, poor social
skills and aggressive behaviour. She developed seizures at
6 years of age, which were characterised by absence sei-
zures with eyelid myoclonia (Jeavons syndrome) and
confirmed by video electroencephalogram (EEG). Her
medications included lamotrigine and ethosuximide. She
also had auditory neuropathy consistent with bilateral
mild loss of peripheral auditory function at higher fre-
quencies. Her physical examination revealed that she had
subtle dysmorphic features, with a square-shaped face,
high forehead, short philtrum, thin upper vermillion
border of the lip and prominent columella. She had mild
thoracic scoliosis, fusion of the proximal interphalangeal
joint in both thumbs, bilateral fifth-finger brachydactyly,
tapered fingers and cutaneous 2-3 syndactyly of the toes.Her neurological examination was normal, with the excep-
tion of frequent episodes of eyelid fluttering bilaterally. An
MRI scan taken when she was 9 years of age was normal,
as was a skeletal survey; however, an abdominal ultra-
sound showed a duplex right kidney. She had a normal
acylcarnitine profile and normal plasma amino acids, elec-
trolytes, lactate, urinary organic acids and FRAXA and
FRAXE fragile X syndrome tests.
Patient 2
Patient 2 is a 9-year-old girl who has a 210-kb deletion
affecting CHD2, the ASB9P1 noncoding pseudogene, the
uncharacterised LOC100507217 noncoding gene and
microRNA MIR3175 (Figure 1), similar to patient 1. She
was referred to medical genetics for mild delays in
motor and language development as well as seizures.
She was born at term (41 weeks gestation) after an un-
eventful pregnancy to nonconsanguineous parents. Her
birth weight was 3,610 g (50th percentile). She was
found to have mild axial hypotonia as an infant. She first
walked at age 15 months. She had feeding problems in
infancy. She was diagnosed with attention-deficit/hyper-
activity disorder and was being treated with dextroam-
phetamine and amphetamine. She showed limited social
skills without any other features associated with ASD.
She had visual perceptual disabilities, a communication
disorder characterised by mixed receptive and expressive
language difficulties and short-term memory problems.
She repeated grade 1, and her performance on the
Wechsler Intelligence Scale for Children–Fourth Edition
was classified in the Low Average range for her age
group. Absence seizures that began at 3 years of age
were being treated with levetiracetam and valproic acid.
Her physical examination showed that she had reduced
body fat mass, a prominent forehead, a triangular face,
full lips, widely spaced maxillary central incisors and
Table 1 Clinical characteristics of patients with CHD2 deletionsa
Characteristics Patient 1 Patient 2 Patient 3 Patient 4 Pinto et al. [10] Capelli et al. [9]
Gender F F F F M F
Age (yr) 11 9 6 16 Not specified 6
Chr15 deletion [hg19]
start–end (bp)
93,324,047 to 93,515,100 93,286,333 to 93,496,391 93,456,168 to 93,534,338 93,563,564 to 93,800,894 93,399,003 to 93,482,000 93,412,860 to 93,923,856
Size 191 kb 210 kb 78 kb 237 kb 83 kb 511 kb
RefSeq genes CHD2, ASB9P1,
LOC100507217, MIR3175
CHD2, ASB9P1,
LOC100507217, MIR3175
CHD2 CHD2, RGMA CHD2, LOC100507217,
MIR3175
CHD2, RGMA,
LOC100507217, MIR3175
Inheritance De novo De novo De novo De novo De novo De novo
Development Motor delay Communication disorder
(receptive and expressive
language difficulties)
Globally delayed Globally delayed with more
significant speech delay
Unknown Globally delayed
Speech delay Speech impairment
Cognition Learning disability Learning disability ID ID ID Unknown
Short-term memory
problems
Short-term memory problems
Visual perceptual disability
Behaviour Short attention span ADHD Aggressive, impulsive,
repetitive behaviours
ASD ASD Autistic behaviour
Limited social skills Aggressive behaviourAggressive behavior Short attention span
Limited social skills
Seizure type
(age of onset)
Jeavons syndrome Absence seizures (3 yr) No epilepsy Complex partial and
generalised seizures
No epilepsy Unspecified seizures (2 yr)
Absence seizures
Eyelid myoclonia (6 yr)
Brain MRI Normal Not done Normal Normal Altered angular gyrus No severe abnormalities
Other Mild hypotonia Mild hypotonia Mild hypotonia Tourette’s syndrome Gait ataxia
Feeding difficulties Feeding difficulties Slight hypotonia
Dysmorphic features Square-shaped face Triangular face Brachycephaly Protruding ears Facial gestalt suggestive
of Angelman syndrome
Prominent forehead Broad forehead Micrognathia
High forehead Short nose, upturned tipFull lips
Prominent columella Widely spaced central
maxillary incisors
Wide mouth
Widely spaced teethShort philtrum
Fifth-finger brachydactyly Micrognathia Prognathia
Syndactyly of toes 2 and 3
Other features Mild thoracic scoliosis Reduced body fat mass Strabismus Mild thoracic scoliosis Strabismus
PIP joint fusion of thumbs
Mild peripheral hearing loss
(higher frequencies)
Duplex kidney
aADHD, Attention-deficit hyperactivity disorder; ASD, Autism spectrum disorder; Chr, Chromosome; ID, Intellectual disability; MRI, Magnetic resonance imaging; PIP, Proximal interphalangeal; RefSeq, National Center for
Biotechnology Information (NCBI) Reference Sequence Database (http://www.ncbi.nlm.nih.gov/refseq/).
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Investigations performed for the assessment of her sei-
zures and developmental delays included G-banding
karyotype, a metabolic screen including carnitine level
and acylcarnitine profile, plasma amino acids, and urin-
ary organic acids, all of which were normal. An EEG
showed generalised epileptogenic dysfunction and photo-
sensitivity. No brain imaging was performed.
Patient 3
Patient 3 has a de novo 78-kb intragenic deletion affect-
ing several 5′ exons of CHD2. No other gene was de-
leted in this patient. This 6-year-old girl was referred to
the clinical genetics clinic for assessment of her pro-
found delay in motor development and hypotonia. Her
mother’s pregnancy was unremarkable, and she was born
by Caesarean section at term with a birth weight of
2,920 g (25th percentile) to healthy nonconsanguineous
parents. She had feeding difficulties as an infant and had
ongoing issues with chewing and swallowing food prop-
erly in early childhood. She was found to have mild
hypotonia in infancy, but she had normal tone at age
6 years. She sat upright at 9 months of age and walked
at 26 months. At 6 years of age, she was not able to
climb stairs with alternating feet and had difficulty ped-
aling a tricycle. She had mild delays in her fine motor
skills, and, although she had normal speech, her lan-
guage comprehension skills were delayed. She scored
below the first percentile on the Wechsler Preschool and
Primary Scale of Intelligence–Third Edition full-scale IQ
test at 4 years of age. She displayed repetitive behaviours,
such as walking in circles, mouthing objects and head-
banging, but she did not meet the criteria for ASD. She
had a history of aggressive behaviour towards others,
which has mostly resolved. She was described as having
lack of insight and judgment, as well as impulsive behav-
iour. She had never had seizures, and her EEG and brain
MRI were normal. Her medical history is significant for
strabismus. Her physical examination revealed that she
had normal growth parameters, including a normal head
circumference. Her facial features included brachyceph-
aly, a broad forehead with a short nose, and an upturned
nasal tip. Her physical examination was otherwise unre-
markable. Molecular genetic testing showed normal
results for methylation-specific MLPA analysis for Prader-
Willi and Angelman syndromes, MECP2 sequencing and
FRAXA fragile X syndrome testing.
Patient 4
Patient 4 was found to have a 237-kb de novo deletion
involving CHD2 and RGMA. Analysis by aCGH in this
16-year-old girl was performed because of poorly con-
trolled epilepsy as well as ASD. She is known to have very
challenging behavioural issues and Tourette’s syndrome.She presented in childhood with delays in motor, speech
and cognition, with a more significant delay in language.
At school, she exhibited difficulties in spelling and reading
skills and had difficulty with mathematics. Her IQ ranged
between 35 and 49. Complex partial and generalised sei-
zures were noted between 3 and 24 months of age. Her
physical examination showed that she had normal
growth parameters with mild thoracic scoliosis. No strik-
ing dysmorphic features were reported. Her brain MRI
was normal.
Discussion
We present the clinical features of four individuals with
heterozygous de novo deletions affecting CHD2 who
were identified from among a phenotypically heteroge-
neous cohort of 42,313 patients with developmental de-
lays or ID, multiple congenital anomalies and/or ASD.
The clinical symptoms of our patients are consistent
with and include delays in speech and/or motor develop-
ment, seizures, ID and/or learning difficulties, and neu-
robehavioural abnormalities, which may include autistic
features, ADHD and/or aggressive behaviour. Our exam-
ination of 26,826 individuals from 13 control cohorts did
not show any deletion affecting exonic sequences of this
gene, indicating that deletions affecting CHD2 are ex-
tremely rare.
Our review of the literature on CHD2 deletions turned
up one case report describing a de novo deletion affect-
ing CHD2 and RGMA in a patient with speech and
motor delays, including ID, gait ataxia, dysmorphic fea-
tures, autistic features with attention deficit, and seizures
beginning at 24 months of age [9]. These features were
attributed to haploinsufficiency of RGMA and/or CHD2.
In our cohort, only one patient had a heterozygous dele-
tion affecting CHD2 and RGMA. Nevertheless, all of our
patients had similar clinical findings, suggesting that
CHD2 contributes significantly to the broad spectrum of
neurodevelopmental disorders and mild dysmorphic fea-
tures seen in patients with CHD2 deletions (Table 1). In
addition, in an examination of the supplemental data
from genomic CNV analysis of an ASD cohort, Pinto
et al. [10] reported a de novo deletion of CHD2 in one
patient with mild ID and ASD but no seizures [10]. This
suggests that epilepsy may not always be present in pa-
tients with CDH2 haploinsufficiency, as we observed in
one of our four patients. In another report in the litera-
ture, Kulkarni et al. [27] described a de novo transloca-
tion t(X;15)(p22.2;q26.1)dn disrupting CHD2 in a child
with developmental delay, scoliosis and hirsutism. It is
possible, however, that the clinical presentation of their
patient may have been affected by disrupted expression
of other genes near the translocation breakpoints. Inter-
estingly, two of our patients with CHD2 deletions had
mild thoracic scoliosis, suggesting that CHD2 disruption
Table 2 Clinical characteristics of patients with CHD2 single-point DNA mutationa
Characteristics Rauch et al. [12] Carvill et al. [11] Allen et al. [13] Suls et al. [28]
Gender F M F F M M M M M F M
Age (yr) 5.75 17 12 29 12 15 2.5 Unknown 6 24 6
Protein change
(type)
p.Thr604
Leufs*19
(frame shift)
p.Glu1412
Glyfs*64
(frame shift)
p.Arg121*
(frame shift)
p.Gly491
Valfs*13
(frame shift)
p.Arg1644
Lysfs*22
(frame shift)
p.Trp548Arg
(missense)
p.Leu823Pro
(missense)
c.1502+1 G>A
(splice donor)
c.1810-2A>C
(p.?)
c.4971G>A
(p.Trp1657*)
c.1396C>T
(p.Arg466*)
Inheritance De novo De novo De novo De novo De novo De novo De novo De novo De novo De novo De novo
Development Globally
delayed
Mild delay Normal prior
to epilepsy
Unspecified
delay
Normal before
seizure onset
Unspecified
delay
Unspecified
delay
Unspecified
delay
Normal prior
to epilepsy
Normal prior
to epilepsy
Subtle motor
and speech
delay
Cognition Mild ID Moderate ID Severe ID Severe ID Severe ID Moderate ID Severe ID Unknown Moderate ID Moderate ID Mild ID
Behaviour Uncontrolled
behavioural
anomalies
ASDBehavioural
problems
Unknown Unknown Unknown Unknown ASD Unknown Unknown Unknown ASD
ADHD
Seizure type
(age of onset)
AS (5 yr) AtS (1 yr), AS, FS,
MJ, MJ-AS, TC
MJ (1 yr), MA,
NCS, TC, TS
Atypical AS (1 yr),
AtS, LGS, MJ, NCS,
SE, TC, TS
AtS (2 yr), MJ,
SE, TC
TC (3 yr), FDS,
H, MJ
MJ (2.5 yr), FDS,
MJ, MA, TS
TC (6 mo),
Atypical AS, AtS,
FDS, LGS, MS
FS (14 mo),
Atypical AS,
MS, SE, TC
FS (2 yr),
MA, MS, TC
TC (3.5 yr),
Atypical AS,
AtS, FS, H, MS
Brain MRI Unknown Unknown Unknown Unknown Unknown Unknown Unknown Normal Normal Normal Nonspecific
atrophy
Other Right
hemibody
weakness
Dysarthria Mild ataxia
Ataxia
Other features Duane
anomaly
Language
regression
after corpus
callosotomy
aAS, Absence seizure; ASD, Autism spectrum disorder; AtS, Atonic seizure; FDS, Focal dyscognitive seizure; FS, Febrile seizure; H, Hemiclonic; ID, Intellectual disability; LGS, Lennox-Gastaut syndrome; MA, Myoclonic
absence; MJ, Myoclonic jerk; MRI, Magnetic resonance imaging; MS, Myoclonic seizure; NCS, Nonconvulsive status; SE, Status epilepticus; TC, Tonic-clonic; TS, Tonic seizure.
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ported by Kulkarni et al. [27] and as described in the
Chd2-mutant mouse model [5,27]. Together, the consist-
ent clinical features among patients diagnosed by routine
clinical microarray and the de novo occurrence of all de-
letions affecting CHD2 reported thus far support a
causative role of CHD2 haploinsufficiency for develop-
mental delay, intellectual disability, epilepsy and behav-
ioural problems, with phenotypic variability among
individuals (Table 1).
The results of recent studies in which researchers used
massively parallel sequencing in patient cohorts investi-
gated for epilepsy, ASD or ID provide supporting
evidence for a role of CHD2 haploinsufficiency in mani-
festation of the characteristics observed in our patients
(Table 2). Carvill et al. [11] performed sequence analysis
of 66 candidate genes in 500 patients clinically diag-
nosed with epileptic encephalopathy. They found muta-
tions predicted to be pathogenic in four patients with
heterozygous de novo nonsense mutations and in two
patients with de novo missense mutations disrupting the
highly conserved residues in the SNF2-related helicase/
ATPase domain. They described all six of their patients
as having moderate to severe ID in addition to the onset
of myoclonic seizures by 3 years of age. A role for CHD2
in ID is further substantiated by a report of a de novo
frameshift mutation identified by exome sequencing in
one patient [12]. In another report, an exome sequen-
cing screen carried out for de novo mutations in patients
with infantile spasms and Lennox-Gastaut syndrome re-
vealed one patient with a CHD2 missense mutation [13].
More recently, Suls et al. [28] found three patients car-
rying de novo CHD2 sequence mutations who had febrile
seizures followed by therapy-resistant generalised sei-
zures (Table 2). In addition, they showed that a knock-
down of chd2 in zebrafish resulted in clinical and
electrographic seizures [28]. Interestingly, none of our
four patients with a deletion of CHD2 had febrile sei-
zures. These previous studies, together with our present
case series, provide strong evidence that haploinsuffi-
ciency of CHD2 is associated with neurodevelopmental
disabilities. Despite the presence of mild dysmorphic fea-
tures in most patients described thus far, no specific fa-
cial gestalt has yet been reported. In addition, no brain
malformation has been visualised by MRI. Although
massively parallel sequencing studies suggest a strong
association between CHD2 haploinsufficiency and sei-
zures or ID, our study, which is based on broadly ascer-
tained clinical cohorts, shows that such associations are
not always observed. Some phenotypic variability be-
tween individuals seems to be present. Future studies
will reveal whether other genetic factors influence the
phenotype of this disorder or if CHD2 haploinsufficiency
is associated with other phenotypes.Conclusions
Herein we describe the first series of patients with dele-
tions affecting CHD2. We provide additional evidence
that deletions and pathogenic point mutations affecting
CHD2 are associated with neurodevelopmental prob-
lems, which include delays in speech and/or motor de-
velopment, seizures, ID or learning difficulties, minor
dysmorphic features and behaviour problems involving
social difficulties and maladaptive behaviours. Although
haploinsufficiency of CHD2 is associated with a broad
spectrum of neurodevelopmental disorders, we show
that variability in the clinical expression of the pheno-
type can be observed. The overview of all currently re-
ported mutations and their associated phenotypic
features provided in this study provides a valuable re-
source for health-care providers caring for individuals
with CHD2 mutations.
Additional file
Additional file 1: Table S1. Number of patients tested and microarray
platform used by genetic diagnostics laboratories. Table S2. Control
cohorts examined for exonic deletions at CHD2.
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(Kooperative Gesundheitsforschung in der Region Augsburg) Study) and
phs000404.v1.p1 (Collaborative Genetic Study of Nicotine Dependence
(COGEND); The Genetic Architecture of Smoking and Smoking Cessation).
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